Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
Diethylstilbestrol (DES) is a synthetic nonsteroidal estrogen delivered as a vaginal suppository, currently in pre-launch development by Eli Lilly. The mechanism of action and specific therapeutic indications are not disclosed in available data. This product represents a small-molecule hormone replacement or gynecological therapeutic.
Pre-launch stage offers opportunity to build foundational commercial infrastructure; team size and investment level will depend on regulatory approval timing and competitive positioning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With Diethylstilbestrol
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer
Worked on DIETHYLSTILBESTROL at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on a pre-launch product offers exposure to cross-functional launch planning, regulatory strategy, and early market positioning—valuable for career development in pharmaceutical commercialization. However, career visibility and team growth depend on successful regulatory approval and demonstrated commercial potential.